NYX-2925|NYX2925|2012536-16-0

Cas No.:	2012536-16-0
Chemical Name:	(2R,3S)-3-Hydroxy-2-[(4S)-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide
Synonyms:	(2R,3S)-3-Hydroxy-2-[(4S)-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide
SMILES:	O=C1[C@]2(C([H])([H])C([H])([H])C([H])([H])N2C(C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])([H])N1[C@@]([H])(C(N([H])[H])=O)[C@]([H])(C([H])([H])[H])O[H]
Formula:	C₁₄H₂₃N₃O₄
M.Wt:	297.3501
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

NYX-2925 has a low potential for "off-target" activity, as it did not exhibit any significant affinity for a large panel of neuroactive receptors, including hERG receptors. NYX-2925 increased MK-801 binding to human N-methyl-D-aspartate receptor NR2A-D subtypes expressed in HEK cells and enhanced N-methyl-D-aspartate receptor current and long-term potentiation (LTP) in rat hippocampal slices (100-500 nM). Single dose ex vivo studies showed increased metaplasticity in a hippocampal LTP paradigm and structural plasticity 24 hours after administration (1 mg/kg p.o.). Significant learning enhancement in both novel object recognition and positive emotional learning paradigms were observed (0.01-1 mg/kg p.o.), and these effects were blocked by the N-methyl-D-aspartate receptor antagonist CPP. NYX-2925 does not show any addictive or sedative/ataxic side effects and has a therapeutic index of >1000. NYX-2925 (1 mg/kg p.o.) has a cerebrospinal fluid half-life of 1.2 hours with a Cmax of 44 nM at 1 hour.NYX-2925, like rapastinel, activates an NMDA receptor-mediated synaptic plasticity process and may have therapeutic potential for a variety of NMDA receptor-mediated central nervous system disorders.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC8824	Traxoprodil	Traxoprodil is an NMDA ε 2 (NR2B) antagonist that has been studied as an alternative to serotonin selective reuptake inhibitors.
DC7863	Talampanel (GYKI 53773)	Talampanel is a novel anticonvulsant that acts as an allosteric inhibitor of the AMPA receptor.
DC8175	Rapastinel(GLYX-13)	Rapastinel(GLYX-13) is a NMDA receptor partial agonist that acts at the glycine site.
DC8307	QNZ46	QNZ is a NR2C/NR2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 μM for NR2D, NR2C, NR2A, NR2B, and GluR1, respectively).
DC7226	Perampanel(E2007）	Perampanel(E2007; ER 155055-90) is a selective noncompetitive AMPA-type glutamate receptor antagonist which has demonstrated anticonvulsant activity in experimental seizure models and antiepileptic activity in clinical trials.
DC7989	PEPA	PEPA is an allosteric modulator of AMPA receptors; binds to the GluA2o and GluA3o LBDs and can be utilized as an indicator of AMPA receptor heterogeneity.
DC11382	NYX-2925	NYX-2925 is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory.
DC7576	NVP-AAM077	NVP-AAM077 is a potent antagonist for NMDA receptors.
DC11406	NBQX	NBQX is a potent aminomethylphosphonic acid receptor (AMPAR) antagonist with an IC50 of 0.7 ± 0.1 μM.
DC7194	MDL 29951	MDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo.